Weakness in Aratana Shares An 'Excellent' Entry Point

Aratana Therapeutics Inc PETX seems to be firing on all cylinders and the recent weakness in shares represents an attractive buying opportunity, Lake Street Capital Markets’ Carl Byrnes said in a report. He reiterated a Buy rating on the company, with a price target of $15.

Analyst Carl Byrnes expressed optimism regarding Aratana Therapeutics being able to emerge as a leading innovator in the companion animal veterinary medicines market. He added, “We perceive the recent weakness as a major buying opportunity.”

Commercialization On The Horizon

Byrnes mentioned that Aratana Therapeutics appears to be on track to commercializing four NCEs this year:

• Galliprant: Approved in March - For control of inflammation and pain associated with osteoarthritis
• Entyce: Approved in May - A breakthrough first-in-class therapeutic for appetite stimulation
• Nocita: ADUFA approval date of August 28 - Liposomal bupivacaine that provides for long duration post-operative pain management
• AT-014 - An immune-vaccine for post-operative treatment of osteosarcoma

Galliprant, Entyce and Nocita seem to be well positioned to becoming blockbuster therapies in the companion animal segment, the analyst added.

Did you like this article? Could it have been improved? Please email feedback@benzinga.com to let us know!